MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular Dynamics will present iCell Sensory Neurons and other key products in its market-leading neuroscience portfolio at the Society for Neuroscience annual conference in Chicago from October 5-9, 2024 and the Annual Pain Therapeutics Summit in Boston from October 28-29, 2024. [Read more…]
AABB Releases New Publication: Getting Started in Processing for Biotherapies
September 10, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the publication of a new book, Getting Started in Processing for Biotherapies, in print and digital formats.
Getting Started in Processing for Biotherapies outlines the major processes to consider in planning for a new or expanded biotherapies processing laboratory and shares how to bring plans from conception to reality. This new essential resource is intended to assist facilities and professionals at the beginning of a journey, covering foundational concepts and requirements and offering options to consider before acting. [Read more…]
Top 4 Most Richly Funded Exosome Startups
In recent years, exosome start-up companies have been the recipients of hundreds of millions of dollars in investor funding. Clearly, investors are feeling favorable toward companies developing exosome products and there is a growing belief that the industry is poised for growth. [Read more…]
Ncardia Launches Panel of Ready-to-Use Assays to Streamline Screening and Selection of New Therapeutic Candidates
New assays based on iPSC help accelerate drug discovery by giving drug innovators in neurodegenerative diseases high quality data on a broad range of disease-relevant read-outs.
September 10, 2024, LEIDEN, Netherlands — Ncardia, a leading human iPSC company, announced today the launch of a new panel of ready-to-use assays designed to streamline the screening and selection of new therapeutic candidates, with a specific focus on neurodegenerative diseases. [Read more…]
BlueRock Receive FDA clearance of IND for Investigational iPSC-derived Cell Therapy OpCT-001
BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases
Cambridge, MA USA, Sept. 03, 2024 — BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. [Read more…]
- « Previous Page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- …
- 338
- Next Page »